arrow
J

James C. Yao

gastrointestinal medical oncology
H指数:80
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2

根据基线时的预后因素,fruquintinib对经过大量预处理的转移性结直肠癌患者的影响: FRESCO-2的探索性分析

2024-06-010
PRE
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

血浆生长激素作为晚期肝细胞癌患者Durvalumab和Tremelimumab的预后生物标志物

2024-03-010
OAAI
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Fruquintinib与安慰剂在难治性转移性结直肠癌患者中的比较 (FRESCO-2): 一项国际,多中心,随机,双盲,3期研究

LANCET
IF88.5
2023-07-01101
PRE
Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
2023-06-011
OA
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

使用pegvisomant阻断生长激素受体信号: 肝细胞癌的功能性治疗策略

2022-10-0614
OAAI
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ

通过ppar δ 重塑肿瘤免疫微环境快速加速KRAS突变胰腺癌的发生

2022-05-1337
OAAI
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

围手术期nivolumab单药治疗与nivolumab联合ipilimumab治疗可切除肝细胞癌: 一项随机,开放标签,2期试验

2022-03-01158
OAAI
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours

神经内分泌肿瘤分子影像学研究的ENETS标准化 (概要) 报告

2021-10-209
OA
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
2021-09-019
OAAI